Glucose, Needle-Free Vaccines Hold Promise For Sontra Ultrasound Device
This article was originally published in The Gray Sheet
Executive Summary
Sontra Medical expects to complete three early-phase clinical studies on its Symphony Diabetes Management System for continuous glucose monitoring in 2005 as part of an exclusive licensing agreement with Bayer Diagnostics
You may also be interested in...
Bayer/Sontra
Continuous, non-invasive glucose monitoring technology development by Sontra gets a boost from $1.5 mil. exclusive, worldwide license pact with glucose monitor company Bayer. The firms anticipate future collaboration agreements for development and commercialization of a monitor incorporating Sontra's SonoPrep ultrasonic skin permeation and biosensor technologies. Baxter will make the initial payment by Jan. 15, 2004, contingent on several factors, including Sontra achieving $2.5 mil. in stockholder equity by Sept. 30 and raising $1.5 mil. from other parties...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.